Lupus, "Rhupus" and "Sjrupus"

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 393-

  Prabhakaran, Sajina ^a   Handler, Richard P ^b  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

^b Adirondack Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; RO ANTIBODY;

ADULT; ANTIBODY TITER; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 79551704906     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100720     Document Type: Letter

References (2)

1. Baer AB, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjögren's syndrome in SLE defines a distinct disease subset. J Rheumatol 2010;37:1143-9.
2. Meijer JM, Meiners PM, Vissink A, Spejkervet FKL, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.